Concord Drugs Stock Performance
|
|
|
Concord Drugs Company background
Founded in: 1995
Managing director: S Nagi Reddy
Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue BioAdhesive, tablets, capsules and ophthalmic preparations and Readytofill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad. State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Readytofill Pellets ensures the highest level of process integrity and product quality.The Company started with Finished Pharmaceutical Formulations and then diversified into Readytofill Pellets, to provide customers with endtoend solution to their various pharmaceutical product needs to commercial contract drug manufacturing. It is engaged in developing New products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. It operates a state of the art, cGMP contract manufacturing FormulationFillFinish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products.
Concord Drugs Financial Highlights
For the full year FY2025–2026, revenue
reached ₹45.26 crore and profit touched at
₹0.34 crore.
Concord Drugs Share Price Today
As of 17 Dec 2025, Concord Drugs share price is ₹82. The stock opened at ₹86.9 and had closed at ₹85.5 the previous day. During today’s trading session, Concord Drugs share price moved between ₹81.22 and ₹86.90, with an average price for the day of ₹84.06. Over the last 52 weeks, the stock has recorded a low of ₹26.10 and a high of ₹92.52. In terms of performance, Concord Drugs share price has increased by 173.8% over the past six months and has declined by 0% over the last year.
Concord Drugs Fundamental
Market Cap (in crs)
82.00
Face Value
10
Turnover (in lacs)
5.18
Key Metrics
Qtr Change %
214.18% Gain from 52W Low
17.3
Dividend yield 1yr %
0
Concord Drugs Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Concord Drugs Quarterly Revenue
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
10.28 Cr | 13.61 Cr | 10.39 Cr | 10.8 Cr | 12.36 Cr |
Concord Drugs Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|
45.26 Cr | 44.93 Cr | 52.09 Cr |
Concord Drugs Quarterly Net Profit/Loss
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
0.19 Cr | 0.12 Cr | 0.04 Cr | 0.23 Cr | 0.04 Cr |
Concord Drugs Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|
0.34 Cr | 0.47 Cr | 0.99 Cr |
Concord Drugs Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
82
Current Price
Day EMA5
83.10
Day EMA10
81.70
Day EMA12
81.30
Day EMA20
80.20
Day EMA26
79.40
Day EMA50
75.80
Day EMA100
68.40
Day EMA200
58.40
Day SMA5
84.30
Day SMA10
79.90
Day SMA20
79.90
Day SMA30
80.80
Day SMA50
75.10
Day SMA100
68.00
Day SMA150
58.90
Day SMA200
52.10
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 5141 Rs | 6314 Rs |
Week Rs | 7535 Rs | 8745 Rs |
Month Rs | 6174 Rs | 8312 Rs |
Resistance & Support
83.37
Pivot
Resistance
First Resistance
85.53
Second Resistance
89.05
Third Resistance
91.21
Support
First Support
79.85
Second support
77.69
Third Support
74.17
Relative Strength Index
54.04
Money Flow Index
45.96
MACD
1.89
MACD Signal
1.55
Average True Range
4.67
Average Directional Index
15.70
Rate of Change (21)
-5.94
Rate of Change (125)
168.32
Concord Drugs Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
73.71 | 117.35 | 70.05 | 132 | 73.48 | 2.37% | -8.06% | -26.74% | -40.07% | -16.00% | 1.64% | 15.77 | 41.17 | 1.17 | |
78.56 | 109.02 | 76.2 | 193 | 79.20 | -3.28% | -8.97% | -23.24% | -51.95% | -3.13% | 1.91% | 15.22 | 41.17 | 1.24 | |
825.15 | 99.02 | 736 | 989.9 | 836.90 | 0.47% | -3.15% | 0.59% | -12.21% | 6.71% | 0.42% | 20.15 | 41.17 | 1.78 | |
7.97 | 103.98 | 7.75 | 20.1 | 8.04 | -1.36% | -16.11% | -37.15% | -58.73% | -47.32% | 0.00% | 0.00 | 41.17 | 1.54 | |
90.00 | 100.04 | 53.8 | 102.5 | 90.85 | -7.41% | 39.00% | 16.88% | 0.00% | 0.00% | 0.00% | 14.73 | 41.17 | 2.22 | |
160.20 | 109.90 | 80.8 | 169 | 161.00 | -4.36% | 9.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 | 41.17 | 5.50 |
Concord Drugs Share Price FAQs
How to buy Concord Drugs shares?
You can easily buy Concord Drugs shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Concord Drugs ?
The 52-week high and low of Concord Drugs share price is ₹92.52 and ₹26.1 as of 17/12/2025.
Please be aware that Concord Drugs stock prices are subject to continuous fluctuations due to various factors.
Invest in Concord Drugs